Table 1 Baseline patient demographic and disease characteristics
Variables | All | Standard | Sequential | P value |
|---|---|---|---|---|
No. patients | 53 | 23 | 30 | |
Age, years, median (IQR) | 28 (24–35) | 32 (26–36) | 28 (24–32) | 0.815 |
Gender, n (%) | 0.877 | |||
Male | 11 (21) | 5 (22) | 6 (20) | |
Female | 42 (79) | 18 (78) | 24 (80) | |
Clinical diagnosis of TSC, n (%) | ||||
With LAM | 31 (58) | 13 (57) | 18 (60) | 0.799 |
With SEGA | 28 (53) | 12 (52) | 16 (53) | 0.933 |
≥ 1 skin lesion | 48 (91) | 21 (91) | 27 (90) | 0.872 |
History of epilepsy | 17 (32) | 7 (30) | 10 (33) | 0.823 |
Family history | 11 (21) | 5 (22) | 6 (20) | 0.877 |
TSC1/2, n (%) | 1.000 | |||
TSC1 mutation | 0 (0) | 0 (0) | 0 (0) | |
TSC2 mutation | 34 (64) | 15 (65) | 19 (63) | |
No mutation | 19 (36) | 8 (35) | 11 (37) | |
Previous treatment, n (%) | ||||
Radical nephrectomy | 6 (11) | 2 (9) | 4 (13) | 0.597 |
Partial nephrectomy | 7 (13) | 3 (13) | 4 (13) | 0.975 |
Artery embolization | 12 (23) | 5 (22) | 7 (23) | 0.891 |
Longest diameter of largest AML, n (%) | 0.912 | |||
≥ 8 cm | 35 (66) | 15 (65) | 20 (67) | |
≥ 3 cm, < 8 cm | 18 (34) | 8 (35) | 10 (33) | |
Bilateral AML, n (%) | 53 (100) | 23 (100) | 30 (100) | 1.000 |
Measurable number of AML, n (%) | 0.912 | |||
1–5 | 18 (34) | 8 (35) | 10 (33) | |
6–10 | 35 (66) | 15 (65) | 20 (67) | |
Total volume of AML, cm3, median (IQR) | 840 (275–1450) | 500 (220–1500) | 880 (300–1425) | 0.815 |